 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...158159160161162163164165166167168...170171» |
- || rivaroxaban / Generic mfg.
Biomarker, New P3 trial: Rivaroxaban for Patients With Antiphospholipid Syndrome (clinicaltrials.gov) - Oct 6, 2016
P3, N=190, Active, not recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Trial primary completion date: MicroVasc-DIVA: Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk (clinicaltrials.gov) - Oct 3, 2016
P3, N=188, Recruiting, Sponsor: GWT-TUD GmbH
Trial primary completion date: Dec 2016 --> Dec 2018
- warfarin / Generic mfg.
Trial initiation date: CANVAS: Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (clinicaltrials.gov) - Oct 3, 2016
P=N/A, N=940, Not yet recruiting, Sponsor: Alliance Foundation Trials, LLC.
Trial primary completion date: Dec 2016 --> Dec 2018 Initiation date: Jun 2016 --> Oct 2016
- ||| pegvorhyaluronidase alfa (PEGPH20) / Halozyme
New trial, Metastases: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=56, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- || rivaroxaban / Generic mfg.
Trial primary completion date: X-PRESS: Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (clinicaltrials.gov) - Sep 23, 2016
P4, N=300, Recruiting, Sponsor: Bayer
Initiation date: Jun 2016 --> Oct 2016 Trial primary completion date: Mar 2017 --> Jun 2017
- ||| Enrollment closed, Trial primary completion date: GEMINI ACS 1: A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (clinicaltrials.gov) - Sep 20, 2016
P2, N=3038, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2017 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Oct 2016
- ||||| rivaroxaban / Generic mfg.
New P4 trial: X-PRESS: Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (clinicaltrials.gov) - Sep 20, 2016
P4, N=300, Recruiting, Sponsor: Bayer
- ||||||| rivaroxaban / Generic mfg.
Trial completion: PIONEER AF-PCI: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (clinicaltrials.gov) - Sep 15, 2016
P3, N=2117, Completed, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Oct 2016 Active, not recruiting --> Completed
- rivaroxaban / Generic mfg.
New trial: Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy? (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=40, Recruiting, Sponsor: Albert Einstein Healthcare Network
- ||||| rivaroxaban / Generic mfg.
New P4 trial, Surgery: VeriXAPPORT: Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm (clinicaltrials.gov) - Sep 14, 2016
P4, N=100, Not yet recruiting, Sponsor: Bayer
- rivaroxaban / Generic mfg.
New trial: Rivaroxaban in Mechanical Valves: RMV Study (clinicaltrials.gov) - Sep 12, 2016
P=N/A, N=0, Available, Sponsor: Hospital Ana Nery
- rivaroxaban / Generic mfg.
New trial: Rivaroxaban in Mechanical Valves: RMV Study (clinicaltrials.gov) - Sep 9, 2016
P=N/A, N=0, Available, Sponsor: Hospital Ana Nery
- rivaroxaban / Generic mfg.
Trial completion: Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2) (clinicaltrials.gov) - Sep 8, 2016
P4, N=70, Completed, Sponsor: London Health Sciences Centre
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Savaysa (edoxaban) / Daiichi Sankyo
Trial primary completion date: PRiSMA-AF: Anticoagulation Preference by AF Patients Study (clinicaltrials.gov) - Sep 7, 2016
P4, N=400, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Dec 2016
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: CASSINI: A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants (clinicaltrials.gov) - Sep 1, 2016
P3, N=700, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Jun 2017 --> Jan 2018
- rivaroxaban / Generic mfg.
Trial suspension, Trial primary completion date: CATHAR: Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (clinicaltrials.gov) - Aug 30, 2016
P2, N=30, Suspended, Sponsor: University Hospital Inselspital, Berne
Trial primary completion date: Jun 2017 --> Jan 2018 Recruiting --> Suspended | Trial primary completion date: Jul 2016 --> Jan 2018
- rivaroxaban / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Naco_Nîmes: Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention (clinicaltrials.gov) - Aug 24, 2016
P=N/A, N=5, Completed, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Suspended | Trial primary completion date: Jul 2016 --> Jan 2018 Recruiting --> Completed | N=10 --> 5 | Trial primary completion date: Jun 2016 --> Jan 2016
- ||| Xarelto (rivaroxaban) / J&J
Enrollment closed, Enrollment change: EINSTEINJunior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) - Aug 22, 2016
P2, N=64, Active, not recruiting, Sponsor: Bayer
Recruiting --> Completed | N=10 --> 5 | Trial primary completion date: Jun 2016 --> Jan 2016 Recruiting --> Active, not recruiting | N=50 --> 64
- || rivaroxaban / Generic mfg.
Trial primary completion date: XASSURE: Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=6000, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=50 --> 64 Trial primary completion date: Jul 2018 --> Apr 2020
- | rivaroxaban / Generic mfg.
Trial initiation date: CIRROXABAN: Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis (clinicaltrials.gov) - Aug 17, 2016
P3, N=160, Recruiting, Sponsor: David Garcia Cinca
Trial primary completion date: Jul 2018 --> Apr 2020 Initiation date: Jan 2016 --> May 2016
- | rivaroxaban / Generic mfg., heparin sodium injection / Generic mfg., apixaban / Generic mfg.
Trial initiation date: VERDICT: Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants (clinicaltrials.gov) - Aug 12, 2016
P3, N=800, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Initiation date: Jan 2016 --> May 2016 Initiation date: Jun 2016 --> Sep 2016
- ||| rivaroxaban / Generic mfg.
New trial: Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=99999, Not yet recruiting, Sponsor: Bayer
- ||||||| Xarelto (rivaroxaban) / J&J, fondaparinux / Generic mfg.
Trial completion, Trial primary completion date: SURPRISE-2011: Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux (clinicaltrials.gov) - Aug 10, 2016
P3, N=476, Completed, Sponsor: GWT-TUD GmbH
Initiation date: Jun 2016 --> Sep 2016 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2016
- ||| Xarelto (rivaroxaban) / J&J
Enrollment open, Surgery: Utilization of TEG to Monitor Rivaroxaban Activity (clinicaltrials.gov) - Aug 2, 2016
P=N/A, N=100, Recruiting, Sponsor: Matthew Neal MD
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: UNIVERSE: Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure (clinicaltrials.gov) - Jul 27, 2016
P3, N=100, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| rivaroxaban / Generic mfg.
Trial completion: XANTUS-EL: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (clinicaltrials.gov) - Jul 26, 2016
P4, N=2101, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || rivaroxaban / Generic mfg.
Trial primary completion date: XANTUS: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (clinicaltrials.gov) - Jul 25, 2016
P=N/A, N=6784, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Mar 2015
- |||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial completion, Trial primary completion date: TripleAXEL: Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation (clinicaltrials.gov) - Jul 23, 2016
P2, N=196, Completed, Sponsor: Asan Medical Center
Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Dec 2015
- || Savaysa (edoxaban) / Daiichi Sankyo
Trial primary completion date: PRiSMA-AF: Anticoagulation Preference by AF Patients Study (clinicaltrials.gov) - Jul 19, 2016
P4, N=400, Recruiting, Sponsor: Bayer
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Dec 2016 --> Sep 2016
- || Savaysa (edoxaban) / Daiichi Sankyo
Trial primary completion date: PRiSMA-AF: Atrial Fibrillation Patient Preference Study (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=400, Recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2016 --> Sep 2016 Trial primary completion date: Jun 2016 --> Nov 2016
- Xarelto (rivaroxaban) / J&J
Enrollment change, Trial termination: XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (clinicaltrials.gov) - Jul 19, 2016
P4, N=10, Terminated, Sponsor: University of Kentucky
Trial primary completion date: Jun 2016 --> Nov 2016 N=60 --> 10 | Not yet recruiting --> Terminated
- warfarin / Generic mfg.
New trial: Direct Oral Anticoagulants and Venous Thromboembolism (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=148859, Completed, Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
- || rivaroxaban / Generic mfg., aspirin / Generic mfg.
New P3 trial, Head-to-Head: INVICTUS-ASA: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority (clinicaltrials.gov) - Jul 14, 2016
P3, N=2000, Not yet recruiting, Sponsor: Population Health Research Institute
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: GALILEO-4D: Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) (clinicaltrials.gov) - Jul 14, 2016
P3, N=300, Recruiting, Sponsor: ECRI bv
- || rivaroxaban / Generic mfg., aspirin / Generic mfg.
New P3 trial, Head-to-Head: INVICTUS-VKA: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority (clinicaltrials.gov) - Jul 14, 2016
P3, N=4500, Not yet recruiting, Sponsor: Population Health Research Institute
- rivaroxaban / Generic mfg.
New P1 trial, Surgery, Bariatric surgery: PK of Rivaroxaban in Bariatric Patients - Extension (clinicaltrials.gov) - Jul 14, 2016
P1, N=13, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
New P2 trial: RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding (clinicaltrials.gov) - Jul 12, 2016
P2, N=50, Not yet recruiting, Sponsor: Indiana University
- ||| rivaroxaban / Generic mfg.
Trial completion, Biopsy: A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants (clinicaltrials.gov) - Jul 6, 2016
P1, N=158, Completed, Sponsor: Janssen Scientific Affairs, LLC
N=60 --> 10 | Not yet recruiting --> Terminated Recruiting --> Completed
- Xarelto (rivaroxaban) / J&J
Trial primary completion date: Einstein Jr: Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates (clinicaltrials.gov) - Jun 24, 2016
P1/2, N=8, Recruiting, Sponsor: Bayer
Recruiting --> Completed Trial primary completion date: Oct 2016 --> Feb 2017
- rivaroxaban / Generic mfg.
Enrollment closed, Trial primary completion date: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer (clinicaltrials.gov) - Jun 23, 2016
P4, N=127, Active, not recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Oct 2016 --> Feb 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016
- | Xarelto (rivaroxaban) / J&J, aspirin / Generic mfg., warfarin / Generic mfg.
New P4 trial, HEOR: PEPPER: Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (clinicaltrials.gov) - Jun 23, 2016
P4, N=25000, Not yet recruiting, Sponsor: Medical University of South Carolina
- | Enrollment change: CLOSE: Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (clinicaltrials.gov) - Jun 19, 2016
P3, N=664, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016 N=900 --> 664
- || Savaysa (edoxaban) / Daiichi Sankyo
Phase classification, Trial primary completion date: PRiSMA-AF: Anticoagulation Preference by AF Patients Study (clinicaltrials.gov) - Jun 17, 2016
P4, N=400, Recruiting, Sponsor: Bayer
N=900 --> 664 Phase classification: P=N/A --> P4 | Trial primary completion date: Jun 2016 --> Dec 2016
- | rivaroxaban / Generic mfg.
Phase classification: XANTUS-EL: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (clinicaltrials.gov) - Jun 16, 2016
P4, N=2101, Active, not recruiting, Sponsor: Bayer
Phase classification: P=N/A --> P4 | Trial primary completion date: Jun 2016 --> Dec 2016 Phase classification: P=N/A --> P4
- | rivaroxaban / Generic mfg.
Phase classification: XANAP: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (clinicaltrials.gov) - Jun 16, 2016
P4, N=2297, Completed, Sponsor: Bayer
Phase classification: P=N/A --> P4 Phase classification: P=N/A --> P4
- || rivaroxaban / Generic mfg.
Enrollment closed: Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=741, Active, not recruiting, Sponsor: Bayer
Phase classification: P=N/A --> P4 Recruiting --> Active, not recruiting
- ||| New trial, Adherence: Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients (clinicaltrials.gov) - Jun 9, 2016
P=N/A, N=28000, Completed, Sponsor: Bristol-Myers Squibb
- ||| rivaroxaban / Generic mfg.
Enrollment change: MERCURY PE: A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department (clinicaltrials.gov) - Jun 5, 2016
P4, N=120, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Active, not recruiting N=300 --> 120
- ||| rivaroxaban / Generic mfg.
New trial: XASSURE: Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (clinicaltrials.gov) - May 27, 2016
P=N/A, N=6000, Recruiting, Sponsor: Bayer
- rivaroxaban / Generic mfg.
Trial completion: RICHAR: Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects (clinicaltrials.gov) - May 25, 2016
P1, N=12, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
N=300 --> 120 Recruiting --> Completed